Stem cell spe­cial­ist Ncar­dia bags new funds to help scale man­u­fac­tur­ing ops

A Bel­gian cell ther­a­py com­pa­ny has se­cured $60 mil­lion in fund­ing to strength­en its man­u­fac­tur­ing op­er­a­tions, and grow the cell and gene ther­a­py ecosys­tem across the world.

Ncar­dia land­ed the fund­ing from Kinic­i­ti, a US in­vest­ment plat­form backed by Welsh, Car­son, An­der­son & Stowe, a New York City pri­vate eq­ui­ty com­pa­ny. The move gives Kinic­i­ti a con­trol­ling stake in Ncar­dia to en­hance any­thing from dis­cov­ery to clin­i­cal pro­grams to com­mer­cial­ized pro­duc­tion, the com­pa­ny said in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER